# Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies:  Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/voluntary-consensus-standards-recognition-program-for-regenerative-medicine-therapies-guidance-for-industry/532afdaa-2167-4373-8507-eb06f5184eff

> FDA guidance document: Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies:  Guidance for Industry. Issue date: October 19, 2023. Get complete insights and analysis.

---

## Details

- Title: Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Biologics Evaluation and Research
- Office URL: /offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d
- Issue Date: 2023-10-19
- Last Changed: 2023-11-27
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2022-D-0745">FDA-2022-D-0745</a>

## Related Documents

- [Labeling of Red Blood Cell Units with Historical Antigen Typing Results:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/labeling-of-red-blood-cell-units-with-historical-antigen-typing-results-guidance-for-industry/39eceff8-0db3-40ad-a2f9-d7dc1cf7df08)
- [Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/compliance-policy-regarding-blood-and-blood-component-donation-suitability-donor-eligibility-and-source-plasma-quarantine-hold-requirements-guidance-for-industry/069f2c62-fbff-4ee9-af16-027d5e3e75a2)
- [Human Gene Therapy for Hemophilia:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/human-gene-therapy-for-hemophilia-guidance-for-industry/bceafce9-c9f0-4137-9ca5-071464212a06)